Mapmygenome appoints leading scientific & strategic advisors to fuel global expansion

New Delhi: Mapmygenome, a pioneer in molecular diagnostics, genetic risk prediction, and microbiome research, has announced the appointment of three globally recognized experts — Dr. B. Brett Finlay, Dr. Bill Mohn, and Mr. Mike Aicher — as Scientific and Strategic Advisors. The move strengthens the company’s scientific leadership and advances its mission to make genomic insights more accessible, actionable, and impactful worldwide.

By bringing together expertise in microbiology, human health, microbial ecology, and international healthcare strategy, Mapmygenome aims to further expand its capabilities in genomics-driven diagnostics and personalized health solutions.

Dr. B. Brett Finlay, Professor at the University of British Columbia and a globally renowned microbiologist, joins as Scientific Advisor. Known for his pioneering work in host-microbe interactions and infectious diseases, particularly in gut health, Dr. Finlay will support the advancement of Mapmygenome’s microbiome-focused diagnostic innovations.

Dr. Bill Mohn, also from the University of British Columbia, is a leading authority in microbial ecology and environmental genomics. As Scientific Advisor, he will contribute to strengthening the company’s research and product development pipeline, particularly in complex microbial community analysis and diagnostic assay development.

Mr. Mike Aicher joins as Strategic Advisor, bringing decades of leadership experience in healthcare operations, commercialization, and global market expansion. He will guide Mapmygenome’s international growth strategy and help build partnerships that enable scalable innovation.

“We are delighted to welcome Dr. Finlay, Dr. Mohn, and Mr. Aicher to the Mapmygenome family,” said Anu Acharya, CEO of Mapmygenome & Microbiome Insights, Inc. “Their combined expertise across science and global strategy will be instrumental in our mission to make genetic information more accessible and actionable for better health outcomes. This marks an important milestone in our journey as a leader in personalized genomics.”

With the support of its new advisors, Mapmygenome will focus on advancing next-generation diagnostics, maintaining rigorous scientific validation across its genomic services, and expanding its global presence through strategic collaborations.